Research programme: cancer therapeutics - Corvus Pharmaceuticals

Drug Profile

Research programme: cancer therapeutics - Corvus Pharmaceuticals

Alternative Names: Adenosine production inhibitor; CPX-006; CPX-016; Humanised anti-CD73 monoclonal antibody; Interleukin-2 inducible kinase inhibitor; ITK Inhibitor; T Cell Reprogramming Drug; T-Cell Reprograming Drug

Latest Information Update: 09 Jun 2017

Price : $50

At a glance

  • Originator Corvus Pharmaceuticals
  • Class Antineoplastics; Monoclonal antibodies; Small molecules
  • Mechanism of Action Emt protein-tyrosine kinase inhibitors; Nucleotidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 07 Apr 2017 Corvus Pharmaceuticals plans a phase I trial for an ITK inhibitor for Cancer in USA (Corvus Pharmaceuticals form 10-K, filed in March 2017)
  • 10 Mar 2017 Preclinical data in Cancer released by Corvus Pharmaceuticals (Corvus Pharmaceuticals form 10-K, filed in March 2017)
  • 10 Mar 2017 Corvus Pharmaceuticals plans a phase I trial for CPX 006 for Cancer in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top